UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): February 22, 2010
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
Laiyang
City, Yantai, Shandong Province, People’s Republic of China 265200
(Address
of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
GENESIS PHARMACEUTICALS ENTERPRISES,
INC.
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of
Operations and Financial Condition.
On
February 22, 2010, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a
press release announcing the Company’s operating results for the second quarter
of 2010 ended December 31, 2009. The Company will host a conference call on
February 26, 2010 at 8:00am Eastern time to discuss its financial results for
the second quarter ended December 31, 2009 of its fiscal year 2010. A copy of
the press release is attached hereto as Exhibit 99.1.
Item
9.01 Financial
Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
Release dated February 22,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
JIANGBO
PHARMACEUTICALS, INC.
|
|
| |
|
|
|
|
By:
|
/s/ Elsa Sung
|
|
|
|
Name:
Elsa Sung
|
|
|
|
Title:
Chief Financial Officer
|
|
Dated:
February 25, 2010